Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women

Climacteric

Volumn 12, Issue SUPPL. 1, 2009, Pages 108-111

  De Villiers, T J ^a,b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Panorama Medi Clinic   (South Africa)

Author keywords

CARDIOVASCULAR DISEASE; POSTMENOPAUSAL WOMEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; CONJUGATED ESTROGEN; LASOFOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; CIS 1R (4' PYRROLIDINOETHOXYPHENYL) 2S PHENYL 6 HYDROXY 1,2,3,4 TETRAHYDRONAPHTHALENE, TARTRATE SALT; CIS-1R-(4'-PYRROLIDINOETHOXYPHENYL)-2S-PHENYL-6-HYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE, TARTRATE SALT; INDOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; TETRALIN DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; ISCHEMIC HEART DISEASE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK; VERTEBRA FRACTURE; CHEMICALLY INDUCED DISORDER; FEMALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INDOLES; POSTMENOPAUSE; PYRROLIDINES; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STROKE; TAMOXIFEN; TETRAHYDRONAPHTHALENES; VENOUS THROMBOEMBOLISM;

EID: 73949097340     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130903010953     Document Type: Article

References (9)

1. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51
2. Ettinger B, Black D, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45 (Pubitemid 29384151)
3. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97 (Pubitemid 29275701)
4. Barrett-Connor E, Grady D, Sashegwayi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA 2002;287:847-57 (Pubitemid 34252031)
5. Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
6. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40:147-55
7. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart Trial. Results of subgroup analyses by age and other factors. Circulation 2009;119:922-30
8. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Min Res 2008;23:525-35 (Pubitemid 351501893)
9. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34